ERBB2 and colorectal carcinoma: According to the recent report, the Guardant360 CDx platform, when used correctly, could identify 28 of 29 (96%) of pretreatment plasma samples of CRC patients as bearing an amplification of ERBB2, thus predicting positive response to HER2-targeted therapy [48].